secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001104659-25-008863
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued
--------------------------------------------------------------------------------

- Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).
- Q4 GAAP EPS $1.48; Non-GAAP EPS $1.72 (includes $0.23 charge for licensing).
- KEYTRUDA full-year sales $29.5B (+18% YoY; +22% ex-FX).
- WINREVAIR full-year sales $419M; GARDASIL declined 3% to $8.6B on lower China demand.
- FY2025 guidance: sales $64.1-65.6B; Non-GAAP EPS $8.88-9.03 (incl. ~$0.09 LaNova charge).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465925008863/0001104659-25-008863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465925008863/tm255059d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-008863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer